Search Results for:Carl O'Donnell
Son is optimistic that U.S. President Donald Trump’s escalation of trade disputes and heightened scrutiny of foreign investments would not affect the Japanese firm’s prolific deal-making.
This is the companies’ third attempt to clinch a deal in the last four years.
The deal comes after Aetna’s $37 billion plan to acquire smaller U.S. health insurance peer Humana Inc was blocked in January by a U.S. federal judge over antitrust concerns.
The move could result in slashing payments to fund managers
A deal could value the entire company at over $9 billion.
The earlier agreed deal value was $1.3 billion.
Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company’s growing oncology roster. Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer… Read more »
Specialty pharmaceutical company Endo International Plc has held discussions with private equity firms about potential asset sales as it seeks to reduce its more than $8 billion debt pile, according to people familiar with the matter. The move underscores the challenges facing the Dublin-based company, which has seen its shares drop… Read more »
If 2015 was a dream year for Wall Street’s top dealmakers, 2016 is starting to take a nightmarish turn.
The U.S. Treasury Department took new steps to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.